Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 37: 1252-1256, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cefalu, W. T.
Right arrow Articles by Smith, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cefalu, W. T.
Right arrow Articles by Smith, J. A.

Clinical Chemistry, Vol 37, 1252-1256, Copyright © 1991 by American Association for Clinical Chemistry

Clinical validation of a second-generation fructosamine assay

WT Cefalu, AD Bell-Farrow, M Petty, C Izlar and JA Smith
Department of Medicine, Bowman Gray School of Medicine, Winston-Salem, NC 27103.

The serum fructosamine assay, used to monitor short-term clinical glycemic control, reportedly has several technical drawbacks. However, technical improvements have resulted in a new second-generation assay of fructosamine. We evaluated this second-generation assay (from Roche Diagnostics) in 529 nondiabetic and diabetic patients and found a highly significant correlation with results of the first-generation assay (r = 0.91, P less than 0.001). Use of the second-generation assay with samples from patients classified on the basis of glycemic control according to their glycohemoglobin (GHb) values, enabled us to discriminate between the nondiabetics, diabetics with "good/moderate" control (i.e., GHb less than 10%), and diabetics with "poor" control (GHb greater than or equal to 10%). We evaluated the validity of the second-generation assay to assess short-term glycemic control in 23 non- insulin-dependent diabetic patients who participated for 10 weeks in an intensive intervention program designed to rapidly normalize the clinical glycemic profile. Results correlated significantly with the one-week average capillary blood glucose concentration (CBG) and with the three-week average CBG in all 23 patients. In addition, the second- generation fructosamine assay results demonstrated a significant decrease at each week of study, as did the average CBG. Results of the first- and second-generation assays correlated significantly at each week of study. GHb correlated significantly with both the second- (r = 0.78, P less than 0.001) and first-generation fructosamine assay results (r = 0.77, P less than 0.001) for the baseline blood samples of the intervention study, but this correlation decreased (to r = 0.35, P = 0.09 and r = 0.34, P = 0.09, respectively) by the conclusion of the study.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
W. T. Cefalu, Z. Q. Wang, A. D. Bell-Farrow, J. Collins, T. Morgan, and J. D. Wagner
Caloric Restriction and Cardiovascular Aging in Cynomolgus Monkeys (Macaca fascicularis): Metabolic, Physiologic, and Atherosclerotic Measures From a 4-Year Intervention Trial
J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2004; 59(10): B1007 - B1014.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. E. Goldstein, R. R. Little, R. A. Lorenz, J. I. Malone, D. Nathan, C. M. Peterson, and D. B. Sacks
Tests of Glycemia in Diabetes
Diabetes Care, July 1, 2004; 27(7): 1761 - 1773.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.